Sarepta Therapeutics Inc (SRPT)

Payables turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Cost of revenue (ttm)	US$ in thousands	530,142	513,430	501,699	457,832	493,584	454,710	409,712	370,552	288,583	287,866	295,843	305,577	306,904	318,537	313,950	314,056	307,813	285,661	268,473	246,088
Payables	US$ in thousands	91,536	164,918	87,948	109,796	106,710	95,875	118,461	56,207	54,007	76,741	44,163	76,681	76,651	111,090	74,528	91,660	26,595	68,094	81,946	44,045
Payables turnover		5.79	3.11	5.70	4.17	4.63	4.74	3.46	6.59	5.34	3.75	6.70	3.99	4.00	2.87	4.21	3.43	11.57	4.20	3.28	5.59

March 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $530,142K ÷ $91,536K
= 5.79

The payables turnover ratio for Sarepta Therapeutics Inc has shown fluctuating trends over the past several quarters. The ratio has ranged from a low of 2.87 to a high of 11.57, indicating varying efficiency in managing its accounts payable during these periods.

A higher payables turnover ratio suggests that the company is able to efficiently pay off its suppliers within a shorter period, which can be favorable as it may indicate strong liquidity or effective working capital management. On the other hand, a lower ratio could imply delayed payments to suppliers, potentially straining relationships or leading to missed opportunities for early payment discounts.

Overall, Sarepta Therapeutics Inc's payables turnover ratio has demonstrated some volatility, and it would be beneficial to closely monitor this metric over time to assess the company's ability to effectively manage its payables and maintain healthy supplier relationships.